Table III.

Th2 Cell-Mediated Survival Advantage is Abrogated by IL-2 Therapy.

		Transplant Components b
Cohort #	Host Tumora	BM	T cells	Th2 Cells	rhIL-2 Injectionc	Days of Post-BMT Survivald	p-valuese
1	−	+	−	−	−	43(43–43)
2	+	+	−	−	−	23(22–26)
3	+	+	+	−	−	33(31–35)
4	+	+	+	−	+	31(27–32)	p=NS (#4 vs. #3)
5	+	+	+	Th2 (WT)	−	42(40–43)	p<0.0001 (#5 vs. #3)
6	+	+	+	Th2 (WT)	+	33(31–36)	p=NS (#6 vs. #3)

^aBALB/c hosts received 850 cGy XRT and host-type TS/A tumor cells (0.1×10⁶ cells).

^bC57BL/6-into-BALB/c (day 0); BM (C57BL/6; 10×10⁶ cells); donor T cells (20×10⁶ cells); donor Th2 cells (WT; 10×10⁶ cells; day 14 post-BMT).

^crhIL-2 50,000 IU/mouse 2×/day I.P. for 5 days beginning at day 14 post BMT.

^dMedian and range for number of days of post-transplant survival; n=7/group.

^eUnpaired t test.